Chronic kidney disease: a contraindication for using biodegradable magnesium or its alloys as potential orthopaedic implants?

Magnesium (Mg) has gained widespread recognition as a potential revolutionary orthopaedic biomaterial. However, whether the biodegradation of the Mg-based orthopaedic implants would pose a risk to patients with chronic kidney disease (CKD) remains undetermined as the kidney is a key organ regulating mineral homeostasis. A rat CKD model was established by a 5/6 subtotal nephrectomy approach, followed by intramedullary implantation of three types of pins: stainless steel, high pure Mg with high corrosion resistance, and the Mg-Sr-Zn alloy with a fast degradation rate. The long-term biosafety of the biodegradable Mg or its alloys as orthopaedic implants were systematically evaluated. During an experimental period of 12 weeks, the implantation did not result in a substantial rise of Mg ion concentration in serum or major organs such as hearts, livers, spleens, lungs, or kidneys. No pathological changes were observed in organs using various histological techniques. No significantly increased iNOS-positive cells or apoptotic cells in these organs were identified. The biodegradable Mg or its alloys as orthopaedic implants did not pose an extra health risk to CKD rats at long-term follow-up, suggesting that these biodegradable orthopaedic devices might be suitable for most target populations, including patients with CKD.